MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

 

Source:  MAIA Biotechnology, Inc. 9/23/2026

 THIO-104 advances toward key 2027 interim survival analysis

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC).

Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually across the two countries. Spain has a substantial lung cancer burden associated with historical tobacco exposure, with lung cancer incidence among women continuing to rise. In Portugal, NSCLC accounts for approximately 82% of lung cancer cases, the highest proportion reported among five European populations evaluated in a comparative study.

“Expanding THIO-104 into Spain and Portugal represents another important step in the execution of our pivotal Phase 3 program,” said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. “Clinical trial participation can provide patients with access to investigational therapies in markets where access to newly approved lung cancer treatments has historically lagged. By establishing THIO-104 sites in Spain and Portugal, we are broadening access to a potentially important new treatment option for patients with advanced NSCLC who have progressed following standard of care treatments.”

To date, THIO-104 has enrolled 65 NSCLC patients resistant to chemotherapy and checkpoint inhibitor treatments at 28 clinical sites in 6 European countries and 10 sites in Taiwan. Among the six European countries, sites in Hungary, Poland, and Turkey are actively enrolling and dosing patients from populations with the highest lung cancer incidence and mortality rates in Europe and globally.¹

MAIA targets 100 patients dosed in THIO-104 by year-end 2026 and expects to have sufficient survival data to conduct an interim data analysis in 2027.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

 

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

 

Source:  MAIA Biotechnology, Inc. 

Strong pace of patient enrollment supports continued advancement toward regulatory milestones

Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). The THIO-104 trial currently has 38 trial sites activated in 6 foreign countries (Taiwan, Romania, Turkey, Georgia, Poland and Hungary).

“Reaching 65 randomized patients marks an important milestone in our Phase 3 trial. With additional clinical sites expected to begin enrolling patients, we remain on track to achieve our goal of more than 100 randomized patients by year-end,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “As we’ve stated previously, statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.¹ We believe third-line NSCLC is an excellent market entry segment due to the substantial unmet medical need in this large immunotherapy-resistant and chemotherapy-resistant population. No current standard of care exists in this NSCLC treatment setting and competition for clinical trial patients is limited.”

In its most recent assessment, ateganosine sequenced with a checkpoint inhibitor showed 90.5% interim disease control rate (DCR) in heavily pretreated 3L NSCLC in MAIA’s ongoing phase 2 THIO-101 clinical trial. This measure contrasts with reported 25%–35% DCRs for standard third-line chemotherapy regimens.

In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that hasn’t been previously approved or marketed.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

 

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

 

 

Source:  MAIA Biotechnology, Inc. 9/16/2026

 

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies 

U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival (OS) beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

“We have worked diligently to advance ateganosine into the U.S. market, and dosing the first patient in the United States represents a major milestone for our ongoing Phase 2 clinical trial,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “Our collaborations with some of the nation’s top institutions and foremost oncologists further strengthen the trial as we evaluate ateganosine for patients in advanced stages of this exceedingly hard-to-treat disease. We believe the data generated through the THIO-101 program may also support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, the study has evolved into a truly global effort focused on addressing a critical unmet need in cancer care.”

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo^®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo^®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

 

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

 

Source:  MAIA Biotechnology, Inc. 9/15/2026

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.

“Our increased investments reflect the confidence we share across our leadership team in MAIA’s science, clinical strategy and long-term commercial potential,” said Dr. Vitoc. “With a growing body of clinical evidence supporting the ateganosine program, we believe MAIA is entering an increasingly important period in its development.”

“As MAIA has stated previously, its ongoing pivotal Phase 3 trial offers a statistically high probability of technical success,” Mr. Guerrero added. “I continue to believe MAIA is well positioned to create a great deal of value for its shareholders over time.”

MAIA’s ongoing pivotal Phase 3 trial THIO-104 evaluates ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer (NSCLC). Statistical assessments of ateganosine suggest a high probability of technical success and potential early full commercial approval if Phase 3 interim data is consistent with Phase 2 THIO-101 trial results. MAIA recently announced positive initial efficacy data from the ongoing Phase 2 THIO-101 clinical trial expansion, Part C, with third-line studies showing a disease control rate (DCR) of 90.5%¹ in the efficacy evaluable population who had at least one tumor scan after starting treatment. 

As of September 14, 2026, MAIA’s directors and officers hold a 21.34% stake in the Company.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

 

Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut

 

Source:  Quantum Cyber N.V. 7/16/2026

Quantum Drones Corporation Closes Purchase of the Real Property Underlying an Approximately 50,000-Square-Foot Industrial Facility; Company Now Owns a Domestic Production Site as It Advances From Technology Licensing to Vertically Integrated Autonomous Defense Manufacturing

Quantum Cyber N.V. (Nasdaq: QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that its wholly owned subsidiary, Quantum Drones Corporation, has completed the acquisition of certain parcels of real property located at 38 Union Avenue, Bridgeport, Connecticut, for a purchase price of $2,300,000. The transaction closed on July 15, 2026.

The closing completes the real-property component of the Bridgeport acquisition that the Company first announced through a Letter of Intent on June 8, 2026, and formalized through definitive agreements announced on June 29, 2026. The real property was acquired from Arcade Realty LLC pursuant to a Purchase and Sale Agreement, entered into in connection with the Company’s separate Asset Purchase Agreement with Arcade Technology LLC covering the installed manufacturing equipment at the site. With the closing, Quantum Cyber now owns the physical facility that it intends to serve as the operating foundation for its domestic autonomous defense manufacturing capability.

The closing marks an important milestone in Quantum Cyber’s previously announced strategic transition from a technology development and IP licensing company to a vertically integrated autonomous defense manufacturer with domestic production capacity under its own control. It follows the Company’s June 2, 2026 announcement that it would assume direct manufacturing of its licensed autonomous drone platform, and its May 28, 2026 announcement of plans to establish a U.S.-based defense-technology manufacturing complex. With the facility now under the Company’s ownership, Quantum Cyber believes it has moved from describing its manufacturing strategy to holding the physical infrastructure on which that strategy depends.

The acquisition is intended to support the Trump Administration’s Executive Order 14307, which establishes American drone dominance as an explicit national security and industrial priority and directs the acceleration of domestic drone production capacity. The U.S. Department of Defense FY2027 Budget Request allocates approximately $55 billion toward drone and autonomous warfare programs, reflecting a doctrinal shift toward high-volume, attritable autonomous platforms deployed at operational scale.

By owning domestic manufacturing infrastructure, Quantum Cyber believes it may be better positioned to participate in this procurement wave as a domestic producer, not solely as a technology licensor.

“When we signed the definitive agreements in June 2026, we said we believed were turning a strategy into a binding commitment. Today we own the facility,” said David Lazar, Chief Executive Officer of Quantum Cyber. “This is no longer a plan on paper — it is a real building, on U.S. soil, that we control. It gives us the domestic production base we have said we were building, and it is the foundation from which we intend to advance toward delivering combat-ready autonomous systems for our government customers. We believe we are moving to the next phase.”

About Quantum Drones Corporation
Quantum Drones Corporation is a wholly owned Nevada-incorporated subsidiary of Quantum Cyber N.V. established to serve as the operational vehicle for the Company’s domestic defense technology programs and U.S. government procurement activities. The subsidiary is led by Peter O’Rourke, President and Director, a former Acting Secretary of the U.S. Department of Veterans Affairs under the Trump administration, and Robert Liscouski, Director, a former Assistant Secretary for Infrastructure Protection at the U.S. Department of Homeland Security and co-founder and former Chairman and CEO of a Nasdaq-listed quantum computing company.

About Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea.

Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

 

Source:  Quantum Cyber N.V. 7/16/2026

Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders.

These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manufacturing of its autonomous defense platforms.

About Quantum Drones Corporation
Quantum Drones Corporation is a wholly owned Nevada-incorporated subsidiary of Quantum Cyber N.V. established to serve as the operational vehicle for the Company's domestic defense technology programs and U.S. government procurement activities. The subsidiary is led by Peter O'Rourke, President and Director, a former Acting Secretary of the U.S. Department of Veterans Affairs under the Trump administration, and Robert Liscouski, Director, a former Assistant Secretary for Infrastructure Protection at the U.S. Department of Homeland Security.

About Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea.

Quantum Cyber Files for Drone Launch System Designed to Field Attritable Autonomous Drones at Scale

 

Source:  Quantum Cyber N.V. 7/14/2026

Rapid-Salvo, Canisterized Launcher Architecture Targets the Pentagon’s Attritable Drone Doctrine and Executive Order 14307 on American Drone Dominance, With Dual-Use Application in Protecting Civilian Infrastructure Against Aerial Intrusion; Developed Through Quantum Drones Corporation for U.S. Federal Defense Procurement

Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) covering a modular drone launch system (the “Launch System”) engineered to deploy autonomous unmanned aerial vehicles rapidly and at scale across defense, border security, and autonomous warfare applications. The application was filed through the Company’s wholly owned subsidiary, Quantum Drones Corporation.

A Structural Shift in U.S. Defense Procurement, and Where the Launch System Fits
U.S. defense procurement is undergoing a shift toward low-cost, autonomous systems deployed at scale, and the ability to field those systems rapidly is emerging as a defining operational requirement. Executive Order 14307 establishes American drone dominance as an explicit industrial and national-security priority, directing the acceleration of domestic drone production, expanded exports of U.S.-made systems, and the enablement of more advanced autonomous operations. The Department of Defense FY2027 Budget Request includes approximately $55 billion allocated to drone and autonomous warfare programs, and the counter-UAS market is projected to grow from $3.1 billion to $10.6 billion by 2030, a 27.2% compound annual growth rate (Grand View Research, 2025).

Central to current doctrine is the concept of “attritable” drones: inexpensive, expendable autonomous platforms deployed in mass rather than in limited numbers. Department of Defense programs including Replicator are operationalizing this model, and operational experience from Ukraine and Indo-Pacific planning has reinforced the same lesson: militaries that can field large numbers of low-cost autonomous systems quickly hold a decisive asymmetric advantage. Launch and deployment is a documented constraint. Fielding drones in mass depends on launch hardware that is modular, transportable, and capable of releasing multiple platforms in rapid succession without extensive setup or fixed infrastructure.

A Modular Architecture for Mass Drone Deployment
The Launch System is designed around a modular, canisterized architecture intended to store, protect, and release autonomous unmanned aerial vehicles in rapid succession. The architecture is designed to be scalable, allowing launch cells to be added or reconfigured according to mission requirements, and to be mountable across ground vehicles, fixed sites, and maritime platforms, supporting multi-domain deployment. The system is designed to support day and night operation and to integrate with the Company’s proprietary ground control system, providing a single interface for mission planning, launch, and coordinated management of deployed platforms, and enabling coordinated release of multiple platforms for swarm operations while minimizing the setup, footprint, and crew burden associated with conventional launch infrastructure.

The Company believes the Launch System also has meaningful dual-use application in protecting civilian and critical infrastructure against aerial intrusion. Deployed in a defensive posture and operating day or night through the Company’s proprietary ground control system, the Launch System is designed to field autonomous platforms rapidly in response to unauthorized drone activity around airports, energy and utility facilities, government sites, and other sensitive locations, extending the technology beyond the battlefield into homeland security and civilian infrastructure protection.

Strategic Positioning Within the Quantum Cyber System-of-Systems Platform
The Launch System is designed as the launch and deployment layer of Quantum Cyber’s multi-domain technology portfolio, complementing the Company’s previously disclosed propulsion, navigation, and swarm-defense intellectual property. The Company’s System-of-Systems platform spans drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications, covering air, land, and sea engagement tiers. The Company believes that launch and deployment intellectual property of this nature is directly additive to that portfolio and strengthens the position of Quantum Drones Corporation as it pursues U.S. government procurement opportunities under the Trump Administration’s defense modernization priorities.

“We are building the autonomous defense platform of the future, and fielding autonomous drones at scale is now as important as the drones themselves,” said David Lazar, Chief Executive Officer of Quantum Cyber. “The Pentagon is seeking approximately $55 billion for drone and autonomous warfare capabilities in its FY2027 budget request, and its doctrine calls for deploying low-cost autonomous systems in mass. This filing extends our System-of-Systems platform into the launch and deployment layer and reinforces the technology foundation Quantum Drones Corporation is building for U.S. federal defense procurement.”

“The United States is entering a new era of defense modernization where autonomy and rapid, resilient deployment will increasingly define strategic advantage,” said Peter O’Rourke, President and Director of Quantum Drones Corporation and former Acting Secretary of the U.S. Department of Veterans Affairs. “Advancing domestic capabilities that allow autonomous systems to be fielded quickly and at scale, whether on the battlefield or in defense of civilian infrastructure, aligns with broader priorities across defense and homeland security and will be essential to maintaining readiness in an increasingly contested environment.”

About Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea.